
IRLAB Therapeutics AB
STO:IRLAB A

Intrinsic Value
The intrinsic value of one
IRLAB A
stock under the Base Case scenario is
16.49
SEK.
Compared to the current market price of 6.78 SEK,
IRLAB Therapeutics AB
is
Undervalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
IRLAB Therapeutics AB
Fundamental Analysis


Revenue & Expenses Breakdown
IRLAB Therapeutics AB
Balance Sheet Decomposition
IRLAB Therapeutics AB
Current Assets | 104.2m |
Cash & Short-Term Investments | 88.6m |
Receivables | 15.6m |
Other Current Assets | 1k |
Non-Current Assets | 55.5m |
PP&E | 8.7m |
Intangibles | 46.9m |
Free Cash Flow Analysis
IRLAB Therapeutics AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
IRLAB Therapeutics AB
Revenue
|
99m
SEK
|
Cost of Revenue
|
-132.2m
SEK
|
Gross Profit
|
-33.2m
SEK
|
Operating Expenses
|
-32.9m
SEK
|
Operating Income
|
-66.1m
SEK
|
Other Expenses
|
-12m
SEK
|
Net Income
|
-78.1m
SEK
|
IRLAB A Profitability Score
Profitability Due Diligence
IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

Score
IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.
IRLAB A Solvency Score
Solvency Due Diligence
IRLAB Therapeutics AB's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Score
IRLAB Therapeutics AB's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IRLAB A Price Targets Summary
IRLAB Therapeutics AB
Dividends
Current shareholder yield for IRLAB A is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IRLAB A
stock under the Base Case scenario is
16.49
SEK.
Compared to the current market price of 6.78 SEK,
IRLAB Therapeutics AB
is
Undervalued by 59%.